Adalimumab is an anti-TNFα monoclonal antibody with immunosuppresive activity [5]. It was the first fully human monoclonal antibody drug approved by the FDA.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Biosimilar drugs: In September 2016, the US FDA approved Amjevita® (ZRC-3197 [1], adalimumab-atto) as a biosimilar to Humira® for multiple inflammatory diseases covered by the reference product label [3]. Additional adalimumab biosimilars such as ABP 501 (Amgen) and SB5 (Samsung Bioepis) are in Phase 3 development (see clinical trials NCT01970475 and NCT02167139 repectively) and FKB327 from Fujifilm Kyowa Kirin Biologics (NCT02260791 recently described in BJCP [6]. |
